All Title Author
Keywords Abstract

PLOS ONE  2013 

Increased Methylglyoxal Formation with Upregulation of Renin Angiotensin System in Fructose Fed Sprague Dawley Rats

DOI: 10.1371/journal.pone.0074212

Full-Text   Cite this paper   Add to My Lib


The current epidemic of obesity and type 2 diabetes is attributed to a high carbohydrate diet, containing mainly high fructose corn syrup and sucrose. More than two thirds of diabetic patients have hypertension. Methylglyoxal is a highly reactive dicarbonyl generated during glucose and fructose metabolism, and a major precursor of advanced glycation end products (AGEs). Plasma methylglyoxal levels are increased in hypertensive rats and diabetic patients. Our aim was to examine the levels of methylglyoxal, mediators of the renin angiotensin system and blood pressure in male Sprague-Dawley rats treated with a high fructose diet (60% of total calories) for 4 months. The thoracic aorta and kidney were used for molecular studies, along with cultured vascular smooth muscle cells (VSMCs). HPLC, Western blotting and Q-PCR were used to measure methylglyoxal and reduced glutathione (GSH), proteins and mRNA, respectively. Fructose treated rats developed a significant increase in blood pressure. Methylglyoxal level and protein and mRNA for angiotensin II, AT1 receptor, adrenergic α1D receptor and renin were significantly increased, whereas GSH levels were decreased, in the aorta and/or kidney of fructose fed rats. The protein expression of the receptor for AGEs (RAGE) and NF-κB were also significantly increased in the aorta of fructose fed rats. MG treated VSMCs showed increased protein for angiotensin II, AT1 receptor, and α1D receptor. The effects of methylglyoxal were attenuated by metformin, a methylglyoxal scavenger and AGEs inhibitor. In conclusion, we report a strong association between elevated levels of methylglyoxal, RAGE, NF-κB, mediators of the renin angiotensin system and blood pressure in high fructose diet fed rats.


[1]  Johnson RJ, Segal MS, Sautin Y, Nakagawa T, Feig DI, et al. (2007) Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 86: 899–906.
[2]  Selvaraju V, Joshi M, Suresh S, Sanchez JA, Maulik N, et al. (2012) Diabetes, oxidative stress, molecular mechanism, and cardiovascular disease–an overview. Toxicol Mech Methods 22: 330–335.
[3]  Stanhope KL (2012) Role of fructose-containing sugars in the epidemics of obesity and metabolic syndrome. Annu Rev Med 63: 329–343.
[4]  Government of Saskatchewan Health website. (2000) Diabetes 2000. Report of the Saskatchewan Advisory Committee on Diabetes. Available: Accessed 07 August 2013.
[5]  Hwang IS, Ho H, Hoffman BB, Reaven GM (1987) Fructose-induced insulin resistance and hypertension in rats. Hypertension 10: 512–516.
[6]  Wang X, Jia X, Chang T, Desai K, Wu L (2008) Attenuation of hypertension development by scavenging methylglyoxal in fructose-treated rats. J Hypertens 26: 765–772.
[7]  Dhar A, Desai K, Kazachmov M, Yu P, Wu L (2008) Methylglyoxal production in vascular smooth muscle cells from different metabolic precursors. Metabolism: Clin Exptl 57: 1211–1220.
[8]  Wang X, Desai K, Chang T, Wu L (2005) Vascular methylglyoxal metabolism and the development of hypertension. J Hypertens 23: 1565–1573.
[9]  Wang X, Chang T, Jiang B, Desai K, Wu L (2007) Attenuation of hypertension development by aminoguanidine in spontaneously hypertensive rats: role of methylglyoxal. Am J Hypertens 20: 629–636.
[10]  Wang H, Meng QH, Gordon JR, Khandwala H, Wu L (2007) Proinflammatory and proapoptotic effects of methylglyoxal on neutrophils from patients with type 2 diabetes mellitus. Clin Biochem 40: 1232–1239.
[11]  McLellan AC, Thornalley PJ, Benn J, Sonksen PH (1994) Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci (London, England : 1979) 87: 21–29.
[12]  Dhar A, Dhar I, Jiang B, Desai KM, Wu L (2011) Chronic methylglyoxal infusion by minipump causes pancreatic beta-cell dysfunction and induces type 2 diabetes in Sprague-Dawley rats. Diabetes 60: 899–908.
[13]  Desai K, Wu L (2007) Methylglyoxal and advanced glycation endproducts: new therapeutic horizons? Rec Pat Cardiovasc Drug Disc 2: 89–99.
[14]  Vander Jagt DL, Hunsaker LA (2003) Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase. Chemico-Biol Interac 143–144: 341–351.
[15]  Wu L, Juurlink BH (2002) Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 39: 809–814.
[16]  Ceriello A, Motz E (2004) Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 24: 816–823.
[17]  Harman D (1998) Aging and oxidative stress. J Int Fed Clin Chem 10: 24–27.
[18]  Ceriello A (2008) Possible role of oxidative stress in the pathogenesis of hypertension. Diabetes Care 31 Suppl 2S181–184.
[19]  Cowley AW Jr, Roman RJ (1996) The role of the kidney in hypertension. JAMA 275: 1581–1589.
[20]  Hall JE, Mizelle HL, Hildebrandt DA, Brands MW (1990) Abnormal pressure natriuresis. A cause or a consequence of hypertension? Hypertension 15: 547–559.
[21]  Manrique C, Lastra G, Gardner M, Sowers JR (2009) The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am 93: 569–582.
[22]  Fyhrquist F, Saijonmaa O (2008) Renin-angiotensin system revisited. J Int Med 264: 224–236.
[23]  Zaman MA, Oparil S, Calhoun DA (2002) Drugs targeting the renin-angiotensin-aldosterone system. Nature Rev Drug Disc 1: 621–636.
[24]  Hitomi H, Kiyomoto H, Nishiyama A (2007) Angiotensin II and oxidative stress. Curr Opin Cardiol 22: 311–315.
[25]  Desai KM, Wu L (2008) Free radical generation by methylglyoxal in tissues. Drug Metabolism Drug Interac 23: 151–173.
[26]  Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS (1999) Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 48: 198–202.
[27]  Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, et al. (1999) Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 58: 1765–1773.
[28]  Desai KM, Gopalakrishnan V, Hiebert LM, McNeill JR, Wilson TW (2006) EDHF-mediated rapid restoration of hypotensive response to acetylcholine after chronic, but not acute, nitric oxide synthase inhibition in rats. Eur J Pharmacol 546: 120–126.
[29]  Dhar A, Desai K, Liu J, Wu L (2009) Methylglyoxal, protein binding and biological samples: are we getting the true measure? J Chromatogr B Analyt Technol Biomed Life Sci 877: 1093–1100.
[30]  Kaufman LN, Peterson MM, Smith SM (1991) Hypertension and sympathetic hyperactivity induced in rats by high-fat or glucose diets. Am J Physiol 260: E95–100.
[31]  Madero M, Perez-Pozo SE, Jalal D, Johnson RJ, Sanchez-Lozada LG (2011) Dietary fructose and hypertension. Curr Hypertens Rep 13: 29–35.
[32]  Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813–820.
[33]  Johnson RJ, Perez-Pozo SE, Sautin YY, Manitius J, Sanchez-Lozada LG, et al. (2009) Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev 30: 96–116.
[34]  Le MT, Frye RF, Rivard CJ, Cheng J, McFann KK, et al. (2012) Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects. Metabolism 61: 641–651.
[35]  Perez-Pozo SE, Schold J, Nakagawa T, Sanchez-Lozada LG, Johnson RJ, et al. (2010) Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes (Lond) 34: 454–461.
[36]  Sanchez-Lozada LG, Tapia E, Jimenez A, Bautista P, Cristobal M, et al. (2007) Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Ren Physiol 292: F423–429.
[37]  Michelotti GA, Price DT, Schwinn DA (2000) Alpha 1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther 88: 281–309.
[38]  Ramasamy R, Yan SF, Schmidt AM (2011) Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 1243: 88–102.
[39]  Wendt T, Bucciarelli L, Qu W, Lu Y, Yan SF, et al. (2002) Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 4: 228–237.
[40]  Rena G, Pearson ER, Sakamoto K (2013) Molecular mechanism of action of metformin: old or new insights? Diabetologia 56: 1898–1906.


comments powered by Disqus